FI910747A - Foerfarande foer framstaellning av acylfoereningar. - Google Patents

Foerfarande foer framstaellning av acylfoereningar. Download PDF

Info

Publication number
FI910747A
FI910747A FI910747A FI910747A FI910747A FI 910747 A FI910747 A FI 910747A FI 910747 A FI910747 A FI 910747A FI 910747 A FI910747 A FI 910747A FI 910747 A FI910747 A FI 910747A
Authority
FI
Finland
Prior art keywords
hydrocarbon
carboxy
foer
cycloaliphatic
aliphatic hydrocarbon
Prior art date
Application number
FI910747A
Other languages
English (en)
Other versions
FI107921B (fi
FI910747A0 (fi
Inventor
Peter Buehlmayer
Franz Ostermayer
Tibur Schmidlin
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25684817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI910747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI910747A0 publication Critical patent/FI910747A0/fi
Publication of FI910747A publication Critical patent/FI910747A/fi
Priority to FI980787A priority Critical patent/FI980787A/fi
Application granted granted Critical
Publication of FI107921B publication Critical patent/FI107921B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Magnetic Record Carriers (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Pyridine Compounds (AREA)
FI910747A 1990-02-19 1991-02-15 Menetelmä terapeuttisesti käyttökelpoisten asyyliyhdisteiden valmistamiseksi FI107921B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI980787A FI980787A (fi) 1990-02-19 1998-04-06 Asyyliyhdisteet

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH51890 1990-02-19
CH51890 1990-02-19
CH223490 1990-07-05
CH223490 1990-07-05

Publications (3)

Publication Number Publication Date
FI910747A0 FI910747A0 (fi) 1991-02-15
FI910747A true FI910747A (fi) 1991-08-20
FI107921B FI107921B (fi) 2001-10-31

Family

ID=25684817

Family Applications (2)

Application Number Title Priority Date Filing Date
FI910747A FI107921B (fi) 1990-02-19 1991-02-15 Menetelmä terapeuttisesti käyttökelpoisten asyyliyhdisteiden valmistamiseksi
FI980787A FI980787A (fi) 1990-02-19 1998-04-06 Asyyliyhdisteet

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI980787A FI980787A (fi) 1990-02-19 1998-04-06 Asyyliyhdisteet

Country Status (26)

Country Link
US (2) US5399578A (fi)
EP (1) EP0443983B1 (fi)
JP (1) JP2749458B2 (fi)
KR (1) KR0171409B1 (fi)
AT (1) ATE134624T1 (fi)
AU (1) AU644844B2 (fi)
CA (2) CA2232775C (fi)
CY (2) CY1978A (fi)
DE (4) DE122010000024I1 (fi)
DK (1) DK0443983T3 (fi)
ES (1) ES2084801T3 (fi)
FI (2) FI107921B (fi)
GR (1) GR3019155T3 (fi)
HK (1) HK219996A (fi)
HU (2) HU219343B (fi)
IE (1) IE71155B1 (fi)
IL (1) IL97219A (fi)
LU (4) LU90100I2 (fi)
LV (1) LV5773B4 (fi)
NL (3) NL970001I2 (fi)
NO (5) NO2007009I2 (fi)
NZ (1) NZ237126A (fi)
PH (1) PH30484A (fi)
PT (1) PT96799B (fi)
SA (1) SA93140130A (fi)
UY (1) UY23835A1 (fi)

Families Citing this family (281)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657498B2 (en) * 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
US5252753A (en) * 1991-11-01 1993-10-12 Ortho Pharmaceutical Corporation Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
DE69230721T2 (de) * 1991-12-27 2000-08-31 Kyowa Hakko Kogyo Co., Ltd. Tricyclische Verbindungen als Angiotensin-II-Antagonisten
ZA931063B (en) * 1992-02-17 1993-09-23 Ciba Geigy Treatment of glaucoma.
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5256658A (en) * 1993-01-15 1993-10-26 Ortho Pharmaceutical Corporation Angiotensin II inhibitors
FR2711367B1 (fr) * 1993-10-19 1995-12-01 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
CA2184712A1 (en) * 1994-03-17 1995-09-21 Marc De Gasparo Treatment of diabetic nephropathy with valsartan
JPH0853424A (ja) * 1994-08-11 1996-02-27 Kureha Chem Ind Co Ltd ベンズイミダゾールスルホン酸アミド誘導体
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
BR9611007A (pt) * 1995-10-06 1999-07-13 Novartis Ag Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
AU1600297A (en) * 1996-02-15 1997-09-02 Novartis Ag Aryl derivatives
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
ATE230263T1 (de) 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
KR980002035A (ko) * 1996-06-17 1998-03-30 손경식 비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6274602B1 (en) 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
US6271244B1 (en) 1998-06-03 2001-08-07 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses
US6187796B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Sulfone hair growth compositions and uses
US6187784B1 (en) 1998-06-03 2001-02-13 Gpi Nil Holdings, Inc. Pipecolic acid derivative hair growth compositions and uses
WO1999062490A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Small molecule sulfonamide hair growth compositions and uses
US6429215B1 (en) 1998-06-03 2002-08-06 Gpi Nil Holdings, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
JP2002516904A (ja) 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) * 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IL140665A0 (en) * 1998-07-10 2002-02-10 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
EP1140071B1 (en) * 1998-12-23 2007-02-21 Novartis AG Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EP1013273A1 (en) * 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
KR20020004974A (ko) 1999-03-19 2002-01-16 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조방법
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
JP4374102B2 (ja) * 1999-09-24 2009-12-02 住友化学株式会社 Ｎ，ｎ−ジイソプロピルエチルアミンの分離方法
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
EP1237888B1 (en) * 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AU1464101A (en) 1999-12-21 2001-07-03 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
NZ540748A (en) 2000-06-22 2007-04-27 Novartis Ag An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
IL153882A0 (en) * 2000-07-19 2003-07-31 Novartis Ag Valsartan salts
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002051799A1 (fr) * 2000-12-26 2002-07-04 Pola Chemical Industries, Inc. Dérivés de biphényle
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
PL368843A1 (en) * 2001-08-28 2005-04-04 Sankyo Company, Limited Medicinal compositions containing angiotensin ii receptor antagonist
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20040072886A1 (en) * 2002-04-15 2004-04-15 Dr. Reddy's Laboratories Limited Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan)
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
WO2004087681A1 (en) * 2003-03-31 2004-10-14 Hetero Drugs Limited A novel amorphous form of valsartan
US7010633B2 (en) * 2003-04-10 2006-03-07 International Business Machines Corporation Apparatus, system and method for controlling access to facilities based on usage classes
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
WO2004094392A1 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
RS20050890A (en) * 2003-05-30 2007-12-31 Ranbaxy Laboratories Limited, Substituted pyrrole derivatives
US7361770B2 (en) * 2003-06-16 2008-04-22 Hetero Drugs Limited Process for preparation of valsartan
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
EA011507B1 (ru) * 2003-08-27 2009-04-28 Зентива А.С. Способ получения калиевой соли лосартана
JP2007504135A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
ZA200601804B (en) * 2003-10-10 2007-05-30 Solvay Pharm Gmbh Pharmaceutcal composition comprising a selective II imidazoline receptor agonist and an angiotensin II receptor blocker
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
HRP20030965A2 (en) * 2003-11-24 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of (s)-n-pentanoyl-n-[[2'-(
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20080161321A1 (en) 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
US8673889B2 (en) 2004-04-26 2014-03-18 Ono Pharmaceutical Co., Ltd. BLT2-mediated disease, BLT2 binding agent and the compound
CZ298471B6 (cs) * 2004-05-19 2007-10-10 Zentiva, A.S. Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu
CN101119747A (zh) * 2004-07-02 2008-02-06 三共株式会社 组织因子产生抑制剂
EP2248520A3 (en) 2004-10-08 2010-11-17 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
WO2006046593A1 (ja) 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited ２以上の置換基を有するベンゼン化合物
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006067216A2 (en) 2004-12-22 2006-06-29 Enantia, S. L. Intermediate compounds for the preparation of an angiotensin ii receptor and process for the preparation of valsartan
ES2397552T3 (es) 2004-12-24 2013-03-07 Krka Composición farmacéutica sólida que comprende valsartán
US7659406B2 (en) * 2005-01-03 2010-02-09 Dr. Reddy's Laboratories Limited Process for preparing valsartan
JP2007527924A (ja) * 2005-01-11 2007-10-04 テバ ファーマシューティカル インダストリーズ リミティド 非晶質バルサルタンの製造方法
EP1714963A1 (en) * 2005-04-19 2006-10-25 IPCA Laboratories Limited Process for the Preparation of Valsartan and its Intermediates
WO2007017897A2 (en) * 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
US20070117987A1 (en) * 2005-07-05 2007-05-24 Viviana Braude Process for preparing valsartan
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AT502219B1 (de) * 2005-08-04 2007-04-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von 5-substituierten tetrazolen
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
WO2007032019A2 (en) * 2005-08-22 2007-03-22 Alembic Limited Process for preparing valsartan
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20070141533A1 (en) * 2005-12-20 2007-06-21 Ford Christopher W Polymeric dental implant assembly
US20070166372A1 (en) * 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
WO2007088558A2 (en) * 2006-02-02 2007-08-09 Alembic Limited A process for purification of valsartan
TW200744583A (en) * 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
US20080004313A1 (en) * 2006-06-28 2008-01-03 Mai De Ltd. Preparation of crystalline polymorphs of rimonabant hydrochloride
WO2008004110A2 (en) * 2006-07-03 2008-01-10 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
MY155277A (en) 2006-08-22 2015-09-30 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20100217008A1 (en) * 2006-12-14 2010-08-26 Ratiopharm Gmbh Process for the preparation of valsartan and intermediate products
MY151993A (en) 2007-01-12 2014-07-31 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
WO2008120242A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
EP2152678A1 (en) * 2007-05-07 2010-02-17 Cipla Limited Process for preparing valsartan
US20080299218A1 (en) * 2007-06-01 2008-12-04 Protia, Llc Deuterium-enriched valsartan
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP1849777B1 (en) * 2007-06-07 2008-10-29 Inke, S.A. Process for obtaining a valsartan salt useful for obtaining valsartan
EP2167477B1 (en) * 2007-06-27 2013-02-27 Mylan Laboratories Limited Process for preparing pure valsartan
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
RU2518098C2 (ru) * 2007-10-05 2014-06-10 Верастэм,Инк. Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ и способ лечения пролиферативных заболеваний
KR20100091963A (ko) 2007-10-09 2010-08-19 노파르티스 아게 발사르탄의 제약적 제형
EP2222273A2 (en) 2007-11-12 2010-09-01 Novartis AG Liquid compositions comprising valsartan
EP2225210B1 (en) 2007-12-11 2012-04-25 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
MX2010007281A (es) * 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2260018A2 (en) * 2008-04-07 2010-12-15 Hetero Research Foundation Process for preparation of valsartan intermediate
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
KR100995734B1 (ko) 2008-05-28 2010-11-19 일동제약주식회사 발사르탄의 개선된 제조방법
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US7863309B2 (en) * 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
EP2352499A1 (en) * 2008-10-10 2011-08-10 Janssen Pharmaceutica, N.V. Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
KR101012135B1 (ko) 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
JP2012533626A (ja) 2009-07-22 2012-12-27 セラヴァンス， インコーポレーテッド 二重作用オキサゾール降圧剤
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
EP2316821A1 (en) * 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
KR101152144B1 (ko) * 2010-02-01 2012-06-15 경동제약 주식회사 발사르탄의 제조 방법 및 이에 사용되는 신규 중간체
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
SI2556059T1 (sl) * 2010-04-07 2014-07-31 Krka, D.D., Novo Mesto Izboljšan proces za pripravo valsartana
CA2796710A1 (en) 2010-04-19 2011-10-27 Cardiolynx Ag Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
WO2012001484A2 (en) 2010-07-02 2012-01-05 Aurobindo Pharma Limited An improved process for the preparation of valsartan
TR201005419A2 (tr) 2010-07-05 2012-01-23 Bi̇lgi̇ç Mahmut Valsartan içeren farmasötik bileşim.
BR112013002589A2 (pt) 2010-08-03 2019-09-24 Novartis Ag valsatana altamente cristalina
MX2013002150A (es) 2010-08-23 2013-04-03 Novartis Ag Proceso para la preparacion de intermediarios para la elaboracion de inhibidores de nep.
BR112013004192A2 (pt) 2010-08-24 2016-05-10 Novartis Ag tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012154249A1 (en) * 2011-02-17 2012-11-15 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
FR2977253B1 (fr) 2011-06-30 2013-08-09 Centre Nat Rech Scient Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9522873B2 (en) 2011-08-05 2016-12-20 Dongguk University Industry-Academic Cooperation Foundation Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases
KR101708538B1 (ko) 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
AP2014007766A0 (en) 2011-12-15 2014-07-31 Takeda Pharmaceuticals Usa Inc Combination os azilsartan and chlorthlidone for treating hypertension black patients
MX2014007933A (es) 2011-12-26 2014-07-30 Novartis Ag Comprimidos y agentes recubiertos en seco.
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3338776A1 (en) 2012-05-01 2018-06-27 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
PL2887961T3 (pl) 2012-08-24 2021-11-08 Novartis Ag Inhibitory nep do leczenia chorób charakteryzujących się powiększeniem lub przebudową przedsionka
WO2014118721A1 (en) 2013-01-30 2014-08-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage forms comprising valsartan and nebivolol
EP2977048A4 (en) 2013-03-12 2017-04-26 LG Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
US20160206597A1 (en) 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
PL3626270T3 (pl) 2013-08-26 2024-04-08 Novartis Ag Leczenie chorób sercowo-naczyniowych
WO2015056219A1 (en) 2013-10-18 2015-04-23 Ranbaxy Laboratories Limited Process for simultaneous drying and micronization of valsartan
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072386A (zh) * 2014-06-28 2014-10-01 浙江华海药业股份有限公司 一种缬沙坦中间体的改进方法
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP6382736B2 (ja) * 2015-02-02 2018-08-29 株式会社トクヤマ バルサルタンの製造方法
PT3294283T (pt) 2015-05-11 2023-06-07 Novartis Ag Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
JP2018516267A (ja) 2015-05-29 2018-06-21 ノバルティス アーゲー 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
EP3307720A1 (en) 2015-06-12 2018-04-18 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CA2989740C (en) 2015-07-23 2023-07-11 Bayer Pharma Aktiengesellschaft Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
US20190054069A1 (en) 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN109641856B (zh) * 2016-09-02 2022-09-30 南京诺瑞特医药科技有限公司 缬沙坦二钠盐的晶型
CN107056720A (zh) * 2016-12-30 2017-08-18 湖南千金湘江药业股份有限公司 一种缬沙坦的制备和纯化方法
EP3342400A1 (en) 2016-12-31 2018-07-04 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. A pharmaceutical composition comprising valsartan and chlorthalidone
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
KR20230161541A (ko) 2017-07-07 2023-11-27 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
ES2881317T3 (es) 2017-07-28 2021-11-29 Synthon Bv Composición farmacéutica que comprende sacubitrilo y valsartán
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10548838B1 (en) 2018-12-14 2020-02-04 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
US11446243B1 (en) 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
EP3939967A1 (en) 2020-07-15 2022-01-19 KRKA, d.d., Novo mesto A continuous process for the preparation of (s)-methyl n-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)-n-pentanoylvalinate in a flow reactor
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
US11655220B2 (en) 2020-10-22 2023-05-23 Hetero Labs Limited Process for the preparation of angiotensin II receptor blockers
CN113387805B (zh) * 2021-07-21 2024-01-12 黑龙江立科新材料有限公司 基于烷基重氮盐取代反应的化合物的制备方法
WO2024019957A1 (en) * 2022-07-18 2024-01-25 Celgene Corporation Compounds for the treatment of neurodegenerative diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973975A (en) * 1962-05-23 1964-11-04 Painton & Co Ltd Improvements in or relating to electric switches
SE307365B (fi) * 1966-05-28 1969-01-07 Yoshitomi Pharmaceutical
US4301169A (en) * 1978-11-14 1981-11-17 Eisai Co., Ltd. Novel imidazole compound and anti-depressing agent containing the same
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4333943A (en) * 1980-04-24 1982-06-08 Miles Laboratories, Inc. Ethyl 3-(3-indolyl)-3-(5-tetrazolyl) propionate compounds used as anti-hypertensive agents
JPS59128376A (ja) * 1983-01-13 1984-07-24 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
EP0142754A2 (en) * 1983-11-04 1985-05-29 Ferrer Internacional, S.A. 2-Substituted-benzoic acid imidazoles, process for preparing them and pharmaceutical compositions containing them
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
US4578386A (en) * 1984-02-10 1986-03-25 Usv Pharmaceutical Corp. 7,8-Dihydroimidazo[1,5-a]pyrazin-8-ones
US4755518A (en) * 1985-12-20 1988-07-05 Warner-Lambert Company Imidazolyl or tetrazolyl substituted benzoic acid derivatives and pharmaceutical compositions thereof
US4748245A (en) * 1986-03-20 1988-05-31 Stauffer Chemical Company Process for making phenylthiopyrimidines
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4812462A (en) * 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
JPS6323868A (ja) * 1986-07-11 1988-02-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンギオテンシン２受容体遮断性イミダゾ−ル
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4870186A (en) * 1987-05-22 1989-09-26 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4874867A (en) * 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US4921632A (en) * 1987-08-26 1990-05-01 Nec Corporation Liquid crystal compounds and compositions
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5189048A (en) * 1988-01-07 1993-02-23 E. I. Du Pont De Nemours And Company Substituted 1,2,3 triazole angiotensin II antagonists
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0403158A3 (en) * 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
CA2018438C (en) * 1989-06-14 2000-08-08 Joseph Alan Finkelstein Imidazolyl-alkenoic acids
DE69025473T2 (de) * 1989-06-30 1996-10-17 Du Pont Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
KR950009860B1 (ko) * 1989-06-30 1995-08-29 이. 아이. 듀퐁 드 네모아 앤드 캄파니 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
US5164407A (en) * 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
EP0412594B1 (en) * 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
EP0411507B1 (en) * 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IE902909A1 (en) * 1989-08-11 1991-02-27 Ici Plc Nitrogen compounds
US5100897A (en) * 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5298518A (en) * 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) * 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
EP0430709A3 (en) * 1989-12-01 1992-02-12 Glaxo Group Limited Benzthiophen derivatives
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5104891A (en) * 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
EP0522038A4 (en) * 1990-03-30 1993-05-26 Merck & Co. Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides

Also Published As

Publication number Publication date
DE59107440D1 (de) 1996-04-04
NL300285I1 (nl) 2007-10-01
IE71155B1 (en) 1997-01-29
FI980787A0 (fi) 1998-04-06
CY2010009I2 (el) 2010-07-28
HU219343B (en) 2001-03-28
FI107921B (fi) 2001-10-31
CA2232775C (en) 2003-06-10
US5399578A (en) 1995-03-21
DK0443983T3 (da) 1996-03-18
PT96799A (pt) 1991-10-31
GR3019155T3 (en) 1996-05-31
HU9100537D0 (en) 1991-09-30
CA2036427C (en) 1998-12-29
HK219996A (en) 1997-01-03
CY1978A (en) 1997-09-05
IL97219A0 (en) 1992-05-25
UY23835A1 (es) 1995-03-21
AU644844B2 (en) 1993-12-23
AU7115191A (en) 1991-08-22
NO910630D0 (no) 1991-02-18
SA93140130A (ar) 2005-12-03
SA93140130B1 (ar) 2005-10-16
NO2010008I1 (no) 2010-05-03
NZ237126A (en) 1994-11-25
KR0171409B1 (ko) 1999-02-01
NL970001I2 (nl) 1997-06-02
NL980036I2 (nl) 2001-02-01
LU90362I2 (fr) 1999-05-10
DE122007000050I1 (de) 2007-11-08
FI910747A0 (fi) 1991-02-15
PT96799B (pt) 1998-09-30
NO910630L (no) 1991-08-20
EP0443983A1 (de) 1991-08-28
LU91676I2 (fr) 2010-06-07
NL980036I1 (nl) 1999-02-01
LV5773B4 (lv) 1997-04-20
HU9802895D0 (en) 1999-02-01
CY2010009I1 (el) 2010-07-28
JPH04235149A (ja) 1992-08-24
IE910548A1 (en) 1991-08-28
DE19675036I2 (de) 2004-10-21
IL97219A (en) 1995-12-08
NL970001I1 (nl) 1997-03-03
CA2036427A1 (en) 1991-08-20
FI980787A (fi) 1998-04-06
NO2007009I1 (no) 2007-07-23
PH30484A (en) 1997-05-28
NO2007009I2 (no) 2010-09-13
US5965592A (en) 1999-10-12
CA2232775A1 (en) 1991-08-20
LU91347I2 (fr) 2009-01-14
KR910021387A (ko) 1991-12-20
DE122010000024I1 (de) 2010-07-08
NO304023B1 (no) 1998-10-12
JP2749458B2 (ja) 1998-05-13
LV5773A4 (lv) 1996-12-20
NO1999001I2 (no) 2007-04-23
HUT61271A (en) 1992-12-28
HU220073B (hu) 2001-10-28
ATE134624T1 (de) 1996-03-15
EP0443983B1 (de) 1996-02-28
ES2084801T3 (es) 1996-05-16
NO1998024I1 (no) 1998-10-21
LU90100I2 (fr) 1997-09-25

Similar Documents

Publication Publication Date Title
FI910747A (fi) Foerfarande foer framstaellning av acylfoereningar.
MY116542A (en) New inhibitors of platelet aggregation.
SE9301911D0 (sv) New peptide derivatives
MY108261A (en) Water soluble camptothecin derivatives
SE9603283D0 (sv) New compounds
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
IL110254A0 (en) Phenalkylamines and their use
DE602004007181D1 (de) 2,4,6-tris(4'aminobenzaldineopentylmalonat)-s-triazin, dieser enthaltenden Sonnenschutzzusammensetzungen und dessen Verwendungen
ATE132136T1 (de) Antitumor anthracenderivate

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20020008

Spc suppl protection certif: L20020009

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L201

Extension date: 20120124

Spc suppl protection certif: L200

Extension date: 20110512

SPCF Supplementary protection certificate application filed

Free format text: SPC L20070019

Spc suppl protection certif: L20070019

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 238

Extension date: 20160215

SPCF Supplementary protection certificate application filed

Free format text: SPC C20100010

Spc suppl protection certif: C20100010

SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 200

Extension date: 20111112

SPCG Supplementary protection certificate granted
SPCR Lapse or expiry of a supplementary protection certificate

Spc suppl protection certif: L20020002 201

SPCR Lapse or expiry of a supplementary protection certificate

Spc suppl protection certif: 238

Spc suppl protection certif: 284